The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...
With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical ...
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) ...
Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on ...
Dupixent approved in China as the first-ever biologic medicine for patients with COPDApproval follows EU approval of Dupixent for adults with ...
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an ...
After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...